T-cell immunotherapy: Looking forward

Jacqueline Corrigan-Curay, Hans Peter Kiem, David Baltimore, Marina O'Reilly, Renier J. Brentjens, Laurence Cooper, Stephen Forman, Stephen Gottschalk, Philip Greenberg, Richard Junghans, Helen Heslop, Michael Jensen, Crystal Mackall, Carl June, Oliver Press, Daniel Powell, Antoni Ribas, Steven Rosenberg, Michel Sadelain, Brian TillAmy P. Patterson, Robert C. Jambou, Eugene Rosenthal, Linda Gargiulo, Maureen Montgomery, Donald B. Kohn

Research output: Contribution to journalArticlepeer-review

46 Scopus citations

Abstract

The rapidly expanding field of T-cell immunotherapy has experienced clinical successes along with some serious toxicities. "T Cell Immunotherapy: Optimizing Trial Design," a workshop sponsored by the National Institutes of Health's (NIH's) Office of Biotechnology Activities (OBA), brought together researchers to discuss the scientific advances and share new data on key trial design issues, including the selection of new targets, optimizing the T-cell population, preconditioning regimens, strategies to promote persistence of cells, and analysis and management of acute reactions to T-cell infusions with the goal of identifying best practices and a research agenda that will facilitate further development and maximize the safety of this promising approach.

Original languageEnglish (US)
Pages (from-to)1564-1574
Number of pages11
JournalMolecular Therapy
Volume22
Issue number9
DOIs
StatePublished - Sep 2014

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Fingerprint

Dive into the research topics of 'T-cell immunotherapy: Looking forward'. Together they form a unique fingerprint.

Cite this